Andere Sprachen Cara Therapeutics, Inc.

Aktien

A1XDTK

US1407551092

CARA

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:28:08 30.04.2024			% 5 Tage	% 1. Jan.
0,763 ^USD	+0,99 %		+7,48 %	+2,29 %

22.03.	Cara Therapeutics, Inc. gibt den Rücktritt von Dr. Joana Goncalves als Chief Medical Officer mit Wirkung zum 16. April 2024 bekannt	CI
06.03.	CARA THERAPEUTICS, INC. : erhält Kaufen-Rating von Canaccord Genuity	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	22.03.
Cara Therapeutics to Host Notalgia Paresthetica Virtual KOL Event on Wednesday, March 27, 2024	08.03.
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	07.03.
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	07.03.
Cara: Q4 Earnings Snapshot	04.03.
Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	04.03.
Earnings Flash (CARA) CARA THERAPEUTICS Reports Q4 Revenue $3M, vs. Street Est of $9.1M	04.03.
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	04.03.
North American Morning Briefing : Stock Futures -2-	04.03.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	12.02.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	12.02.
Cara Therapeutics to Cut Workforce Up to 50%, Halt Work on Chronic Kidney Disease; Chief Scientific Officer to Exit	22.01.
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026	22.01.
Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program	22.01.
Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024	22.01.
Top Midday Decliners	18.12.
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis	18.12.
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis	18.12.
Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from NASDAQ Biotechnology Index	15.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cara Therapeutics, Inc.

Aktien

A1XDTK

US1407551092

CARA

Andere Sprachen

Filter